Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Patent metadata

Field	Value
Publication number	US-11891434-B2
Application number	US-201815988348-A
Country	US
Kind code	B2
Filing date	May 24, 2018
Priority date	Nov 30, 2010
Publication date	Feb 6, 2024
Grant date	Feb 6, 2024

Abstract

An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

First claim

The invention claimed is:

1. A method of removing a soluble antigen from plasma, the method comprising:
(a) identifying an individual in need of having the antigen removed from the individual's plasma; and
(b) administering to the individual an antibody that is able to remove the antigen from plasma, thereby removing the antigen from the individual's plasma,
wherein the antibody comprises an antigen-binding domain and a human FcRn-binding domain,
wherein the antibody binds to the antigen through the antigen-binding domain of the antibody and has a KD(Ca 2+ 3 μM)/KD(Ca 2+ 2 mM) value, defined as the ratio of KD for the antigen at a 3 μM calcium ion concentration and KD for the antigen at a 2 mM calcium ion concentration, of 2 to 10,000, when KD is measured using a surface plasmon resonance technique under the following conditions:
37 degrees Celsius, pH 7.4, a running buffer comprising 0.05% polysorbate 20,
10 mmol/L N-(2-acetamido)-2-aminoethanesulfonic acid (ACES), 150 mmol/L NaCl,
and either 3 μM or 2 mM CaCl 2 , and where the antibody is immobilized on a CM4 sensor chip, and the antigen serves as analyte,
wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo,
wherein the antibody is a human IgG or a humanized IgG,
wherein the antigen-binding domain comprises a light chain variable domain and a heavy chain variable domain,
wherein at least four positions selected from Kabat numbering positions 30, 31, 32, 50, and 92 of the light chain variable domain are occupied by amino acids independently selected from serine, asparagine, aspartic acid, glutamic acid, histidine, and tyrosine, and
wherein at least one of the at least four positions is occupied by glutamic acid or aspartic acid.

2. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 31, and 32 of the light chain variable domain.

3. The method of claim 1 , wherein one of the at least four positions is Kabat numbering position 50 of the light chain variable domain.

4. The method of claim 1 , wherein one of the at least four positions is Kabat numbering position 92 of the light chain variable domain.

5. The method of claim 1 , wherein the heavy chain variable domain comprises Kabat numbering positions 95, 96, 100a, and 101, and wherein at least three positions selected from Kabat numbering positions 95, 96, 100a and 101 of the heavy chain variable domain are occupied by amino acids independently selected from serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, histidine, and tyrosine.

6. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 31, and 50 of the light chain variable domain.

7. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 31, and 92 of the light chain variable domain.

8. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 31, 32, and 50 of the light chain variable domain.

9. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 31, 32, and 92 of the light chain variable domain.

10. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 32, and 50 of the light chain variable domain.

11. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 32, and 92 of the light chain variable domain.

12. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 30, 50, and 92 of the light chain variable domain.

13. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 31, 50, and 92 of the light chain variable domain.

14. The method of claim 1 , wherein three of the at least four positions are Kabat numbering positions 32, 50, and 92 of the light chain variable domain.

15. The method of claim 1 , wherein each of Kabat numbering positions 30, 31, 32, 50, and 92 of the light chain variable domain is occupied by an amino acid independently selected from serine, asparagine, aspartic acid, glutamic acid, histidine, and tyrosine.

16. The method of claim 1 , wherein each of Kabat numbering positions 30, 31, 32, 50, and 92 of the light chain variable domain is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

17. The method of claim 1 , wherein each of at least two of the at least four positions is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

18. The method of claim 1 , wherein each of at least three of the at least four positions is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

19. The method of claim 1 , wherein each of the at least four positions is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

20. The method of claim 5 , wherein each of Kabat numbering positions 95, 96, 100a, and 101 of the heavy chain variable domain is occupied by an amino acid independently selected from serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, histidine, and tyrosine.

21. The method of claim 5 , wherein each of Kabat numbering positions 95, 96, 100a, and 101 of the heavy chain variable domain is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

22. The method of claim 5 , wherein at least one of the at least three heavy chain variable domain positions is occupied by glutamic acid or aspartic acid.

23. The method of claim 5 , wherein each of at least two of the at least three heavy chain variable domain positions is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

24. The method of claim 5 , wherein each of the at least three heavy chain variable domain positions is occupied by an amino acid independently selected from glutamic acid and aspartic acid.

25. The method of claim 1 , wherein binding of the antigen to the antibody is lower at pH 5.8 than at pH 7.4.

26. The method of claim 1 , wherein the FcRn-binding domain is a modified Fc domain that has FcRn-binding activity at pH 7.4, wherein the amino acid sequence of the modified Fc domain varies from the sequence of a wild type Fc domain at one or more of positions 248, 250, 252, 254, 255, 256, 257, 258, 265, 286, 289, 297, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434, and 436 (EU numbering).

27. The method of claim 1 , wherein the antigen is human IL-6, a soluble form of human IL-6 receptor, a soluble form of human CD4, human IgA, a soluble form of human glypican 3, or human IgE.

28. The method of claim 1 , wherein one or more of Kabat numbering positions 31, 32, and 92 in the light chain variable domain are occupied by aspartic acid.

29. The method of claim 1 , wherein one or both of Kabat numbering positions 31 and 32 in the light chain variable domain are occupied by aspartic acid.

30. The method of claim 1 , wherein Kabat numbering positions 31 and 32 in the light chain variable domain are both occupied by aspartic acid.

31. The method of claim 1 , w

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Igawa Tomoyuki
• Ishii Shinya
• Funaki Miho
• Hironiwa Naoka
• Maeda Atsuhiko
• Nezu Junichi
• Ruike Yoshinao
• Baba Takeshi
• Shimizu Shun

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K16/248

  IL-6 · CPC title

• C07K16/2866 Primary

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K16/4291

  against IgE · CPC title

• G01N33/53

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title